Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2023-01-21 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, related to dematerialization of securities for the quarter ended December 31, 2022. It is a compliance certificate issued by the Registrar and Share Transfer Agent to the stock exchanges. The document is short (2653 characters) and primarily serves as a regulatory compliance filing rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a certificate confirming regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2023-01-21 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about the closure of the trading window for insiders due to upcoming unaudited financial results for the quarter ended December 31, 2022. It references regulatory compliance with insider trading regulations but does not contain any financial data, results, or detailed report content. The document is an announcement related to trading restrictions rather than a financial report or earnings release. Given its nature and length (1250 characters), it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2023-01-02 English
Amalgamation/Merger
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding the approval of a Scheme of Amalgamation by the National Company Law Tribunal (NCLT). It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material event disclosures. The document is short (1352 characters) and serves as an announcement of a corporate event (amalgamation approval) rather than a detailed report or filing. It does not contain financial statements or detailed merger documentation but informs the exchanges and public about the approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2022-12-24 English
Related Party Transaction
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) regarding related party transactions for the half year ended September 30, 2022. It references compliance with SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, specifically Regulation 23(9), which mandates disclosure of related party transactions. The content includes detailed tables of transactions, values, counterparties, and other financial details for the half-year period. This is a regulatory disclosure document focused on related party transactions rather than a full financial report or earnings release. It is not an announcement of a report publication but the actual disclosure itself. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory compliance disclosure that does not fit into other specific categories like Annual Report or Interim Report.
2022-11-28 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is a short announcement from the company to stock exchanges about the outcome of a board meeting held on November 14, 2022. It states that the Board approved the unaudited financial results for the quarter and half year ended September 30, 2022, and the limited review report from the statutory auditor. The document does not contain the actual financial results or detailed financial data but rather informs about the approval and availability of these reports on the company's and stock exchanges' websites. The document length is only 1504 characters, which is quite short and fits the pattern of an announcement rather than a full financial report. According to the "Menu vs Meal" rule, this is an announcement of the report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain the full report or detailed financial data.
2022-11-14 English
Board Meeting — Financial results
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled to consider and approve unaudited financial results for the quarter and half year ended September 30, 2022. It is an intimation of the meeting date and agenda, not the financial results report itself. The document is short (1767 characters) and serves as a notification rather than containing substantive financial data or analysis. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and meeting intimation under SEBI regulations, rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2022-11-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.